AR103461A1 - Método de uso de la respuesta al anticuerpo anti-acetato de glatirámero - Google Patents
Método de uso de la respuesta al anticuerpo anti-acetato de glatirámeroInfo
- Publication number
- AR103461A1 AR103461A1 ARP160100142A ARP160100142A AR103461A1 AR 103461 A1 AR103461 A1 AR 103461A1 AR P160100142 A ARP160100142 A AR P160100142A AR P160100142 A ARP160100142 A AR P160100142A AR 103461 A1 AR103461 A1 AR 103461A1
- Authority
- AR
- Argentina
- Prior art keywords
- glatiramer acetate
- months
- initial dose
- human subject
- month
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Métodos para inducir anticuerpos anti-acetato de glatirámero específicos en un sujeto humano afectado por esclerosis múltiple, que comprende administrar al sujeto humano tres inyecciones subcutáneas de una dosis de 40 mg/ml de acetato de glatiramero por semana durante por lo menos 12 meses, de modo tal que el nivel de anticuerpos anti-GA específicos en la sangre o el suero del sujeto humano i) aumenta durante hasta aproximadamente 6 meses después de administrar una dosis inicial de 40 mg/ml de la administración de acetato de glatirámero al sujeto humano; ii) aumenta a un índice mayor durante el primer mes después de la dosis inicial de 40 mg/ml de acetato de glatirámero en comparación con el índice de aumento después del primer mes al tercer mes después de la dosis inicial de 40 mg/ml de acetato de glatirámero; iii) alcanzan un pico aproximadamente 3 o aproximadamente 6 meses o entre aproximadamente 3 y aproximadamente 6 meses después de la dosis inicial de 40 mg/ml de acetato de glatirámero; y iv) es más alto que el nivel basal por lo menos durante aproximadamente 12 meses después de la dosis inicial de 40 mg/ml de acetato de glatirámero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562109033P | 2015-01-28 | 2015-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103461A1 true AR103461A1 (es) | 2017-05-10 |
Family
ID=56433699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100142A AR103461A1 (es) | 2015-01-28 | 2016-01-20 | Método de uso de la respuesta al anticuerpo anti-acetato de glatirámero |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160213633A1 (es) |
| AR (1) | AR103461A1 (es) |
| TW (1) | TW201639591A (es) |
| UY (1) | UY36537A (es) |
| WO (1) | WO2016123344A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11167003B2 (en) | 2017-03-26 | 2021-11-09 | Mapi Pharma Ltd. | Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1513553B1 (en) * | 2002-05-21 | 2008-11-19 | Mayo Foundation For Medical Education And Research | Methods and materials for treating and diagnosing kallikrein-6 related inflammatory conditions |
| AU2008304313B2 (en) * | 2007-09-26 | 2013-01-10 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| US8709433B2 (en) * | 2010-10-11 | 2014-04-29 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate |
-
2015
- 2015-07-15 US US14/800,014 patent/US20160213633A1/en not_active Abandoned
- 2015-12-25 TW TW104143903A patent/TW201639591A/zh unknown
-
2016
- 2016-01-20 AR ARP160100142A patent/AR103461A1/es unknown
- 2016-01-25 UY UY0001036537A patent/UY36537A/es not_active Application Discontinuation
- 2016-01-28 WO PCT/US2016/015369 patent/WO2016123344A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20160213633A1 (en) | 2016-07-28 |
| TW201639591A (zh) | 2016-11-16 |
| UY36537A (es) | 2016-08-31 |
| WO2016123344A1 (en) | 2016-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019065028A5 (es) | ||
| DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| AR099078A2 (es) | Un medicamento que comprende acetato de glatiramer | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| MX355065B (es) | Método y dispositivo para conmutación de cámaras. | |
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| BR112016012506A8 (pt) | combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| AR102096A1 (es) | Proceso para elaborar acetato de glatiramer | |
| CL2018000002A1 (es) | Agente terapéutico y método para tratar el síndrome de hunter. | |
| CO2017008395A2 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol | |
| HRP20201388T1 (hr) | Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| MX2017008000A (es) | Sistema de inyeccion de un solo uso. | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| AR103461A1 (es) | Método de uso de la respuesta al anticuerpo anti-acetato de glatirámero | |
| PE20221338A1 (es) | Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| IL274563B1 (en) | Methods of use and preparations containing dolaglutide | |
| BR112017012975A2 (pt) | formulações injetáveis de paracetamol | |
| BR112022004723A2 (pt) | Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração | |
| Martín-Morales et al. | Efficacy and safety of two dosing regimens with Tadalafil in Spanish men with erectile dysfunction: results from the SURE study in 14 European countries | |
| AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente | |
| Buie | Pancreatitis: case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |